Research Activities<\/h1>\n

Some of the research work and research studies on which our staff\nhave been involved
\n <\/p>\n

\n

\n

\n

\n \n

\n

\n

ADReSS<\/b>\n
HIV AIDS Drug Resistance Surveillance Study<\/b>\n
(2014 \u2013 2018)<\/b>\n <\/h2>\n

NIH Funded project
Study of the predictors of HIV-1 drug resistance after\nfailure of 1st-line ART using a novel durable measure of ART adherence and\ndetermine the clinical significance of drug-resistant minority variants in\nperi-urban and rural settings in KZN. Enrolment of 1000 participants across 2\nstudy sites. 
Partners \u2013 UKZN, Emory, Harvard, US CDC, KZN DOH, IALCH \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n \n

\n

\n

REVAMP <\/b>\n
(2016 \u2013 2021)<\/b>\n <\/h2>\n

NIH Funded project
In an effort to optimize the global\nHIV care continuum and foster sustained control of the HIV epidemic, the Joint\nUnited Nations Programme on HIV\/AIDS (UNAIDS) has set a \u201c90-90-90\u201d treatment\ntarget for 2020.The goal of this study is to\ndetermine whether the addition of routine resistance testing, to guide\nmanagement of virologic failure and sustain the successful completion of the\nHIV continuum of care, improves clinical outcomes and reduces costs for\npatients with virologic failure on first-line therapy in sub-Saharan Africa. The results of this study will be a\nuseful resource for public health programmers, ministries of health and\nmultinational partners to optimize the clinical management of virologic failure\nin the region.
Partners \u2013 Harvard, Emory, MGH, UKZN, KZN DOH, HEARD, IALCH\n <\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n \n

\n

\n

OASIS
Optimizing Adherence Support Inspiring Success
(2019 - 2021)\n <\/h2>\n

The aim of this study is\nto monitor the treatment journey of multidrug-resistant\ntuberculosis (MDR-TB) patients and how this affects their response to\nthe treatment as well as to better understand why patients may fail to complete\nthe new MDR-TB treatment and to learn what we can do to help them complete the\ntreatment course. \n \nAlthough\nthe new and shorter treatment regimen (9-11 months depending), according to\nmost doctors, will be easier for patients to take and complete, some patients\nmay struggle to complete this shorter treatment. This is why the study will\nalso focus on understanding why patients may fail to complete this new MDR-TB\ntreatment and learning what we can do to assist them in finishing the treatment\ncourse.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n

\n

\n \n

\n

\n

AWACC<\/b>\n
Annual Workshop on Advanced Clinical Care - AIDS 
(2014 \u2013 2019)<\/b>\n <\/h2>\n

This annual conference providing updates in clinical management and public health programmes for HIV and TB. It includes presentations from local and international experts. The interactive workshop translates the latest evidence-based research and apply best practice models of care into good clinical practice, specifically for resource constrained areas.  The workshop receives great acclaim from delegates for its relevance to the growing ART roll out programme in South Africa (SA). We form part of the conference secretariat as a partner to Medicate AIDS \u2013 NGO<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n \n

\n

\n

ZINK<\/b>\n
Safer Conception for Women - Understanding use of Periconception PrEP
(2018 \u2013 2021)<\/b>\n <\/h2>\n

We provide data management and Quality Assurance services. to this PrEP Study. Partners on rhis project are Harvard University (Partners), MRU (MatCH Research Unit), the UAB (the University of Alabama at Birmingham)<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n \n

\n

\n

Healthy Families<\/b>\n
PrEP\nProject<\/b> 
(2019 - 2020)\n <\/h2>\n

Adherence to periconception HIV risk-reduction among\nuninfected women in rural Uganda. We provide data management and Quality Assurance services. to this PrEP Study. Partners on rhis project are Harvard University (Partners), MRU (MatCH Research Unit),\nthe UAB (the University of Alabama at Birmingham)<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n

\n

\n \n

\n

\n

Enhancing Drug-Resistant Tuberculosis Patient Care In Ethekwini, Kwazulu-Natal, South Africa
(2018)<\/b>\n <\/h2>\n

This was a Quality\nImprovement Project 2013 \u2013 2018 (2018). It was an initiative of the KwaZulu-Natal Department of Health\n(KZN DOH), King Dinuzulu Hospital Complex (KDHC), the South African Red Cross\nSociety and Partners. Project funded by Eli-Lilly Foundation and United Way\nWorldwide. We conducted an Impact Assessment Study to determine the efficacy of the programme.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n \n

\n

\n

King Dinuzulu Hospital Complex<\/b>\n
(KDHC)<\/b>\n
TB Heroes Project<\/b>\n
(2018)<\/b>\n <\/h2>\n

We partnered with The Sentinel Project, The Health Ninja, and Umduduzi to celebrate the treatment supporters for children living with TB. W conduced workshops to train and inform the supporters of advances in TB managment.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

\n \n

\n

\n

Genomics<\/b>\n
Sub-Study of ADReSS<\/b>\n
(2020-2022)<\/b>\n <\/h2>\n

NIH Funded Project
Multi-omic\nPredictors of Renal Function among HIV-infected Individuals of African Ancestry<\/b>\n
Partners - Emory University\n <\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n \n \n \n \n \n \n","protected":false},"excerpt":{"rendered":"

Research Activities Some of the research work and research studies on which our staff have been involved ADReSS HIV AIDS Drug Resistance Surveillance Study (2014 \u2013 2018) NIH Funded projectStudy of the predictors of HIV-1 drug resistance after failure of 1st-line ART using a novel durable measure of ART adherence and determine the clinical significance … Continue reading “Research”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":7,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-116","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=\/wp\/v2\/pages\/116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=116"}],"version-history":[{"count":1,"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=\/wp\/v2\/pages\/116\/revisions"}],"predecessor-version":[{"id":139,"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=\/wp\/v2\/pages\/116\/revisions\/139"}],"wp:attachment":[{"href":"https:\/\/adrenergy.co.za\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}